Ataturk University, Medical Faculty, Department of Thoracic Surgery, Erzurum, Turkey.
Ataturk University, Medical Faculty, Department of Radiology, Erzurum, Turkey.
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):779-783. doi: 10.1016/j.arbres.2019.07.014. Epub 2019 Aug 14.
Pulmonary alveolar echinococcosis (PAE) is a chronic disease caused by Echinococcus multilocularis with very low incidence in developed countries.
This single-center, retrospective study included 34 patients who were diagnosed with PAE between January 2001 and February 2019 (15 males, 19 females, mean age: 52.4±15.8 years, age range: 28-78 years) in Ataturk University Medical School, Erzurum, Turkey.
The liver was the primary involved organ in all cases. Pulmonary involvement was detected in 13.0% (34/261) of all cases with hepatic alveolar echinococcosis (AE), and three patients (8.8%) had both pulmonary metastasis and brain metastasis. The route of spread to the lungs based on radiological data was hematogeneous in 25 patients (73.5%), transdiaphragmatic in three patients (8.8%) and both hematogeneous and transdiaphragmatic in six patients (17.7%). AE showed bilateral involvement in 19 patients (55.9%), whereas only the right lung was involved in 12 patients (35.3%) and the left lung in three patients (8.8%). Of the patients, five underwent surgery due to PAE and 29 patients received medical therapy with albendazole. A total of three patients died during the follow-up period (2, 5 and 10 years after the diagnosis of PAE), while 31 patients continued with follow-up and treatment for a mean duration of 5.4±3.8 years (1-14 years).
Patients with hepatic AE must, as a matter of course, be screened for possible lung involvement. Albendazole therapy may slow down disease progression in patients with widespread pulmonary involvement who are not eligible for surgery.
肺泡状棘球蚴病（PAE）是一种由多房棘球绦虫引起的慢性疾病，在发达国家发病率很低。
本单中心回顾性研究纳入了 2001 年 1 月至 2019 年 2 月期间在土耳其埃尔祖鲁姆阿塔图尔克大学医学院诊断为 PAE 的 34 例患者（男性 15 例，女性 19 例，平均年龄 52.4±15.8 岁，年龄范围 28-78 岁）。
所有病例的主要受累器官均为肝脏。在所有肝泡状棘球蚴病（AE）患者中，有 13.0%（34/261）肺部受累，3 例（8.8%）患者既有肺部转移，又有脑转移。根据影像学资料，肺部转移的播散途径为血行性 25 例（73.5%），膈肌转移 3 例（8.8%），血行性和膈肌转移均存在 6 例（17.7%）。AE 双侧受累 19 例（55.9%），右肺受累 12 例（35.3%），左肺受累 3 例（8.8%）。5 例患者因 PAE 行手术治疗，29 例患者接受阿苯达唑药物治疗。在随访期间，共有 3 例患者死亡（PAE 诊断后 2、5 和 10 年），31 例患者继续随访和治疗，平均随访和治疗时间为 5.4±3.8 年（1-14 年）。
肝 AE 患者必须常规筛查肺部受累情况。对于不适合手术的广泛肺部受累患者，阿苯达唑治疗可能会减缓疾病进展。
